Lucy Scott

Raf Kinase Inhibitor Protein Expression in a Survival Analysis of Colorectal Cancer Patients

Fahd Al‐Mulla, Suzanne Hagan, A. Behbehani et al. · Journal of Clinical Oncology · 2006 · 187 citations · Full text

Medicine, Oncology, Pathology +17

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

Ruth Plummer, Paul Lorigan, Neil Steven et al. · Cancer Chemotherapy and Pharmacology · 2013 · 177 citations

Medicine, Oncology, Pharmacology +15

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 122 citations

Medicine, Gynecology, Oncology +13

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer

R. Charles Coombes, Holly Tovey, Lucy Kilburn et al. · JAMA Oncology · 2021 · 47 citations · Full text

Medicine, Oncology, Pharmacology +15

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Jean Abraham, Karen Pinilla, Alimu Dayimu et al. · Nature · 2024 · 47 citations · Full text

Medicine, Oncology, Pharmacotherapy +17